{"id":12,"date":"2018-03-02T12:19:29","date_gmt":"2018-03-02T12:19:29","guid":{"rendered":"http:\/\/www.epipgx.eu\/?page_id=12"},"modified":"2023-01-03T12:37:08","modified_gmt":"2023-01-03T11:37:08","slug":"publications","status":"publish","type":"page","link":"https:\/\/epipgx-eu.lcsb.uni.lu\/index.php\/publications\/","title":{"rendered":"Publications"},"content":{"rendered":"\n
  1. Stevelink R, Al-Toma D, Jansen FE, et al. Individualised prediction of drug resistance and seizure recurrence after medication withdrawal in people with juvenile myoclonic epilepsy: A systematic review and individual participant data meta-analysis. EClinicalMedicine<\/em>. 2022 Nov 11;53:101732. doi:10.1016\/j.eclinm.2022.101732<\/a><\/li>
  2. Campbell C, McCormack M, Patel S, et al. A pharmacogenomic assessment of psychiatric adverse drug reactions to levetiracetam. Epilepsia<\/em>. 2022 Jun;63(6):1563-1570. doi: 10.1111\/epi.17228<\/a><\/li>
  3. Altmann A, Ryten M, Di Nunzio M, et al. A systems-level analysis highlights microglial activation as a modifying factor in common epilepsies. Neuropathology and Applied Neurobiology<\/em>. 2022;48(1):e12758. doi:10.1111\/nan.12758<\/a><\/li>
  4. Wolking S, Campbell C, Stapleton C, et al. Role of Common Genetic Variants for Drug-Resistance to Specific Anti-Seizure Medications. Front Pharmacol<\/em>. 2021;12. doi:10.3389\/fphar.2021.688386<\/a><\/li>
  5. Wolking S, Schulz H, Nies AT, et al. Pharmacoresponse in genetic generalized epilepsy: a genome-wide association study. Pharmacogenomics<\/em>. 2020;21(5):325-335. doi:10.2217\/pgs-2019-0179<\/a><\/li>
  6. Wolking S, Moreau C, Nies AT, et al. Testing association of rare genetic variants with resistance to three common antiseizure medications. Epilepsia<\/em>. 2020;61(4):657-666. doi:10.1111\/epi.16467<\/a><\/li>
  7. Wolking S, May P, Mei D, et al. Clinical spectrum of STX1B<\/em> -related epileptic disorders. Neurology<\/em>. Published online February 8, 2019:10.1212\/WNL.0000000000007089. doi:10.1212\/WNL.0000000000007089<\/a><\/li>
  8. Silvennoinen K, de Lange N, Zagaglia S, et al. Comparative effectiveness of antiepileptic drugs in juvenile myoclonic epilepsy. Epilepsia Open<\/em>. 2019;4(3):420-430. doi:10.1002\/epi4.12349<\/a><\/li>
  9. Lerche H, Sf B, Dh L, undefined. Intestinal-Cell Kinase and Juvenile Myoclonic Epilepsy. N Engl J Med<\/em>. 2019;380(16):e24-e24. doi:10.1056\/nejmc1805100<\/a><\/li>
  10. Feng YCA, Howrigan DP, Abbott LE, et al. Ultra-Rare Genetic Variation in the Epilepsies: A Whole-Exome Sequencing Study of 17,606 Individuals. The American Journal of Human Genetics<\/em>. 2019;105(2):267-282. doi:10.1016\/j.ajhg.2019.05.020<\/a><\/li>
  11. McCormack M, Gui H, Ingason A, et al. Genetic variation in CFH predicts phenytoin-induced maculopapular exanthema in European-descent patients. Neurology<\/em>. 2018;90(4):e332-e341. doi:10.1212\/WNL.0000000000004853<\/a><\/li>
  12. May P, Girard S, Harrer M, et al. Rare coding variants in genes encoding GABAA receptors in genetic generalised epilepsies: an exome-based case-control study. Lancet Neurol<\/em>. 2018;17(8):699-708. doi:10.1016\/S1474-4422(18)30215-1<\/a><\/li>
  13. Berghuis B, Stapleton C, Sonsma ACM, et al. A genome-wide association study of sodium levels and drug metabolism in an epilepsy cohort treated with carbamazepine and oxcarbazepine. Epilepsia Open<\/em>. 2018;0(ja). doi:10.1002\/epi4.12297<\/a><\/li>
  14. Androsova G, Krause R, Borghei M, et al. Comparative effectiveness of antiepileptic drugs in patients with mesial temporal lobe epilepsy with hippocampal sclerosis. Epilepsia<\/em>. 2017;58(10):1734-1741. doi:10.1111\/epi.13871<\/a><\/li>
  15. Allen AS, Berkovic SF, Bridgers J, et al. Application of rare variant transmission disequilibrium tests to epileptic encephalopathy trio sequence data. European Journal of Human Genetics<\/em>. 2017;25(7):894-899. doi:10.1038\/ejhg.2017.61<\/a><\/li>
  16. Leu C, Balestrini S, Maher B, et al. Genome-wide Polygenic Burden of Rare Deleterious Variants in Sudden Unexpected Death in Epilepsy. EBioMedicine<\/em>. 2015;2(9):1063-1070. doi:10.1016\/j.ebiom.2015.07.005<\/a><\/li><\/ol>\n","protected":false},"excerpt":{"rendered":"

    Stevelink R, Al-Toma D, Jansen FE, et al. Individualised prediction of drug […]<\/p>\n","protected":false},"author":2,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":[],"_links":{"self":[{"href":"https:\/\/epipgx-eu.lcsb.uni.lu\/index.php\/wp-json\/wp\/v2\/pages\/12"}],"collection":[{"href":"https:\/\/epipgx-eu.lcsb.uni.lu\/index.php\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/epipgx-eu.lcsb.uni.lu\/index.php\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/epipgx-eu.lcsb.uni.lu\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/epipgx-eu.lcsb.uni.lu\/index.php\/wp-json\/wp\/v2\/comments?post=12"}],"version-history":[{"count":4,"href":"https:\/\/epipgx-eu.lcsb.uni.lu\/index.php\/wp-json\/wp\/v2\/pages\/12\/revisions"}],"predecessor-version":[{"id":186,"href":"https:\/\/epipgx-eu.lcsb.uni.lu\/index.php\/wp-json\/wp\/v2\/pages\/12\/revisions\/186"}],"wp:attachment":[{"href":"https:\/\/epipgx-eu.lcsb.uni.lu\/index.php\/wp-json\/wp\/v2\/media?parent=12"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}